← TrialMatch
HomeTrials

Twenty Years' Experience in Retroperitoneal Lymph Node Dissection for Testicular Cancer in

The aim of this study is to evaluate the oncologic and functional outcomes of RPLND as primary treatment (stage I and IIA-IIB with negative markers) or of residual masses after chemotherapy (PC-RPLND) in the treatment of patients with seminomatous and non-seminomatous. In order to evaluate the role and the͛clinical imp

Condition(s)Testicular Cancer
StatusRecruiting
Study typeObservational
SummaryThe aim of this study is to evaluate the oncologic and functional outcomes of RPLND as primary treatment (stage I and IIA-IIB with negative markers) or of residual masses after chemotherapy (PC-RPLND) in the treatment of patients with seminomatous and non-seminomatous. In order to evaluate the role and the͛clinical impact of different surgical techniques of RPLND will be included patients treated with open, laparoscopic, and robot-assisted techniques
Who can participateInclusion Criteria: * Aged ≥ 18 years * RPLND of residual mass after chemotherapy in patient with testicular neoplasm seminomatous or nonseminomatous performed by open, laparoscopic, or robotic technique * Primary RPLND for seminomatous or nonseminomatous testicular neoplasm of stage I or IIA-IIB with negative markers performed with open, laparoscopic or robotic technique * RPLND performed by open, laparoscopic, or robotic technique for the treatment of tumors seminomatous or nonseminomatous chemiorefractory testicular tumors progressing after I and II line of chemotherapy * Acquisition of informed consent Exclusion criteria: * Patient with comorbidities with contraindication to surgery * Hemorrhagic diathesis RETROSPECTIVE PHASE. Patients with the same inclusion and exclusion criteria as
SexMale
Lead sponsorIRCCS Azienda Ospedaliero-Universitaria di Bologna
LocationsBologna, Bologna, Italy; Milan, Italy, Italy
Start date2021-12-01
NCT IDNCT06806917
Official listinghttps://clinicaltrials.gov/study/NCT06806917

🔍 Search all trials →